植入式心脏警报系统早期识别ST段抬高型心肌梗死
ALERTS试验为多中心随机对照研究,纳入907例高危ACS受试者,评估植入式心脏监测器对快速进展性ST段偏移发出警报的效果。安全性终点达标(系统相关并发症免除率96.7%),但主要复合疗效终点未显著降低(3.8% vs 4.9%)。90天窗口内警报显著缩短检测到就诊时间(51分钟 vs 30.6小时),扩展分析显示阳性预测值更高且假阳性率更低。
要点
- 植入式系统安全性达标,96.7%无系统相关并发症。
- 主要复合疗效终点未显著降低(3.8% vs 4.9%)。
- 90天窗口内警报显著缩短检测到就诊时间。
核心结论
- 植入式心脏系统可检测早期ST段偏移并警报潜在闭塞事件。
- 试验未达预设主要疗效终点,但结果提示在高危受试者中可能有助于识别无症状事件。
研究设计与样本
- 多中心随机对照试验ALERTS(NCT00781118),高危ACS受试者N=907随机分为对照组(警报关闭)或治疗组6个月,之后所有受试者警报激活。
- 主要安全性终点为系统相关并发症免除率>90%;复合主要疗效终点为心源性/不明原因死亡、新发Q波心肌梗死或检测到就诊时间>2小时。
主要发现
- 安全性达标:96.7%免除系统相关并发症(n=30)。
- 确认闭塞事件7天内疗效终点治疗组与对照组无显著降低(16/423 [3.8%] vs 21/428 [4.9%],后验概率=0.786)。
- 90天窗口内警报显著缩短检测到就诊时间(51分钟 vs 30.6小时;Pr[pt<pc]>0.999)。
- 扩展分析中警报开启组阳性预测值更高(25.8% vs 18.2%),假阳性率显著更低(0.164 vs 0.678次/患者年;p<0.001)。
临床怎么用
- 该植入式系统可检测早期ST段偏移并向患者发出警报。
- 虽未达主要疗效终点,但可能在高危受试者中有助于识别无症状事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptoms remain a poor prompt for acute coronary syndromes (ACS). Timely restoration of perfusion in ST-segment elevation myocardial infarction is associated with improved left ventricular function and survival. OBJECTIVES: This report details the results of ALERTS (AngelMed for Early Recognition and Treatment of STEMI), a multicenter, randomized trial of an implantable cardiac monitor that alerts patients with rapidly progressive ST-segment deviation. METHODS: High-risk ACS subjects (N = 907) were randomized to a control (alarms deactivated) or treatment group for 6 months, after which alarms were activated in all subjects. The primary safety endpoint was absence of system-related complications (>90%). The composite primary efficacy endpoint was cardiac/unexplained death, new Q-wave myocardial infarction, or detection to presentation time >2 h. RESULTS: Safety was met with 96.7% freedom from system-related complications (n = 30). The efficacy endpoint for a confirmed occlusive event within 7 days was not significantly reduced in the treatment compared with control group (16 of 423 [3.8%] vs. 21 of 428 [4.9%], posterior probability = 0.786). Within a 90-day window, alarms significantly decreased detection to arrival time at a medical facility (51 min vs. 30.6 h; Pr [pt < pc] >0.999). In an expanded analysis using data after the randomized period, positive predictive value was higher (25.8% vs. 18.2%) and false positive rate significantly lower in the ALARMS ON group (0.164 vs. 0.678 false positives per patient-year; p < 0.001). CONCLUSIONS: The implantable cardiac system detects early ST-segment deviation and alerts patients of a potential occlusive event. Although the trial did not meet its pre-specified primary efficacy endpoint, results suggest that the device may be beneficial among high-risk subjects in potentially identifying asymptomatic events. (AngelMed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118).
引用
- Gibson CM, Holmes D, Mikdadi G, et al. Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019. PMID: 30842028. doi:10.1016/j.jacc.2019.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。